Ruxolitinib: Long-Term Management of Patients with Myelofibrosis and Future Directions in the Treatment of Myeloproliferative Neoplasms
Considerable clinical experience regarding the long-term efficacy and safety of ruxolitinib has been gathered since the drug was approved in the USA for patients with intermediate or high-risk myelofibrosis (MF) in November 2011. Findings from the pivotal phase 3 COMFORT studies showed that ruxoliti...
| Main Authors: | , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Springer US
2014
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223534/ |